In these older patients, CHIP provides a complicating factor for predicting outcomes due to the possibility that sampling effects could lead to transplanted mixtures of mutant and healthy hematopoietic clones that may contribute to post-transplant leukemia. The gene discussed is STUB1; the disease is leukemia.